Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 17/20 | 0.50 |
| ▸ | DRD2 | P14416 | 1/20 | 0.49 |
| ▸ | DRD1 | P21728 | 1/20 | 0.49 |
| ▸ | DRD4 | P21917 | 1/20 | 0.49 |
| ▸ | DRD3 | P35462 | 1/20 | 0.49 |
| ▸ | ADRB1 | P08588 | 8/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3588531 | 0.91 | ADRB2 (0.49) | ADRB2DRD2DRD1DRD4DRD3 | |
| SCHEMBL3603610 | 0.90 | ADRB2 (0.55) | ADRB2DRD2DRD1DRD4DRD3 | |
| SCHEMBL2210578 | 0.85 | ADRB2 (0.68) | ADRB2 | |
| Trifluoroacetic Acid SCHEMBL2212361 | 0.82 | ADRB2 (0.64) | ADRB2 | |
| SCHEMBL3597187 | 0.82 | ADRB2 (0.61) | ADRB2DRD2DRD1DRD4DRD3 | |
| SCHEMBL3596947 | 0.81 | SMYD2 (0.54) | ADRB2DRD2DRD1DRD4DRD3 | |
| SCHEMBL3600903 | 0.81 | SMYD2 (0.54) | ADRB2DRD2DRD1DRD4DRD3 | |
| SCHEMBL3597947 | 0.81 | ADRB2 (0.43) | ADRB2ADRB1 | |
| Trifluoroacetic Acid SCHEMBL3588776 | 0.80 | ADRB2 (0.57) | ADRB2DRD2DRD1DRD4DRD3 | |
| Trifluoroacetic Acid SCHEMBL3594748 | 0.80 | SMYD2 (0.52) | ADRB2DRD2DRD1DRD4DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120142646-A1 | Novel Compounds 621 | ASTRAZENECA AB (SE) | 2012-06-07 | — | — | US | disclosed |
| US-20100056508-A1 | AMINE DERIVATIVES AND THEIR USE IN BETA-2-ADRENORECEPTOR MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2010-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142646-A1 | Novel Compounds 621 | AR, ADRA1D, ADRA1B | ADRB2 18/4885DRD2 23/4885DRD1 45/4885 |
| US-20100056508-A1 | AMINE DERIVATIVES AND THEIR USE IN BETA-2-ADRENORECEPTOR MEDIATED DISEASES | ADRB2, ADRB1, ADRA2A | ADRB2 1/4885DRD2 18/4885DRD1 69/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.